Katalog der Deutschen Nationalbibliothek

Expertensuche ?

Servicezeiten in Frankfurt am Main ab 1. Dezember 2025: Montag bis Freitag 9–18 Uhr und Samstag 10–16 Uhr
Service hours in Frankfurt am Main from 1 December 2025: Monday to Friday 9:00-18:00 and Saturday 10:00-16:00

Leichte Bedienung, intuitive Suche: Die Betaversion unseres neuen Katalogs ist online! → Zur Betaversion des neuen DNB-Katalogs

24. Dezember 2025 bis 1. Januar 2026: Die Deutsche Nationalbibliothek bleibt an beiden Standorten geschlossen. Bestellte Medien werden am 2. Januar 2026 bereitgestellt. // 24 December 2025 to 1 January 2026: The German National Library will be closed at both locations. Ordered media will be made available on 2 January 2026.

Ergebnis der Suche nach: "Originator"
im Bestand: Gesamter Bestand

111 - 120 von 138

	111	Evaluating efficacy and safety of ocrelizumab biosimilar (Xacrel) compared to the originator (Ocrevus) in relapsing multiple sclerosis: a phase III, randomized, equivalency, clinical trial Enthalten in Scientific reports Bd. 14, 22.10.2024, Nr. 1, date:12.2024: 1-12
	112	Evaluating the impact of the single exit price policy on a basket of originator medicines in South Africa from 1999 to 2014 using a time series analysis Enthalten in BMC health services research Bd. 19, 16.8.2019, Nr. 1, date:12.2019: 1-13
	113	Evaluation of adverse events focusing on infection associated with infliximab originator and biosimilar using a spontaneous reporting system database Enthalten in Journal of pharmaceutical health care and sciences Bd. 5, 7.10.2019, Nr. 1, date:12.2019: 1-4
	114	Forced Degradation Products of Liraglutide: A Comparative Study of Similarity Between Originator and Analogue Version by Liquid Chromatography–Mass Spectrometry Enthalten in International journal of peptide research and therapeutics Bd. 30, 24.4.2024, Nr. 3, date:5.2024: 1-13
	115	Forty-Eight-Month Monitoring of Disease Activity in Patients with Long-Standing Rheumatoid Arthritis Treated with TNF-α Inhibitors: Time for Clinical Outcome Prediction and Biosimilar vs Biologic Originator Performance Enthalten in Clinical drug investigation Bd. 44, 31.1.2024, Nr. 3, date:3.2024: 141-148
	116	Immunogenicity, Efficacy, and Safety of Biosimilar Insulin Aspart (MYL-1601D) Compared with Originator Insulin Aspart (Novolog®) in Patients with Type 1 Diabetes After 24 Weeks: A Randomized Open-Label Study Enthalten in BioDrugs Bd. 36, 17.9.2022, Nr. 6, date:11.2022: 761-772
	117	Impact of Introducing Infliximab Biosimilars on Total Infliximab Consumption and Originator Infliximab Prices in Eight Regions: An Interrupted Time-Series Analysis Enthalten in BioDrugs Bd. 37, 23.3.2023, Nr. 3, date:5.2023: 409-420
	118	Impact of switching from the originator adalimumab to a biosimilar: a retrospective cohort study Enthalten in BMC immunology Bd. 26, 3.7.2025, Nr. 1, date:12.2025: 1-13
	119	In Vitro Biological Characterization of Recombinant Insulin Aspart from Biogenomics and Originator Insulin Aspart Enthalten in BioDrugs Bd. 37, 7.6.2023, Nr. 5, date:9.2023: 709-719
	120	Incidence of and Reasons and Determinants Associated with Retransitioning from Biosimilar Etanercept to Originator Etanercept Enthalten in BioDrugs Bd. 35, 26.10.2021, Nr. 6, date:11.2021: 765-772

111 - 120 von 138

Alle Materialarten

Alle Kataloge/Sammlungen

Alle Standorte > Leipzig (138)

Aktionen

Administration